Pictor

Pictor is an international biotechnology and in-vitro diagnostics company developing targeted, multiplexed proteomics platforms for clinical laboratories, research facilities and veterinary health providers. Founded in Auckland, New Zealand, in 2005 by Wanda Lee Mathias and Dr. Anand Kumble, the company was established to bridge the gap between complex mass spectrometry systems and single-analyte ELISA assays.

Its platform combines PictArray, a multiplexed ELISA microarray, PictImager, a benchtop imaging instrument, and Pictorial, proprietary analysis software. Together, these components support the detection and interpretation of multiple biomarkers from a single sample. The system accommodates serum, plasma, whole blood, saliva and raw milk, addressing applications across human and animal health.

Diagnostic development

Pictor works with laboratories and research partners on custom targeted proteomic panels, biomarker assay development, diagnostic validation and Laboratory Developed Test workflows. Its work includes integrating non-invasive specimen types into assays and adapting multiplex testing to laboratory requirements. The company serves clinical diagnostic laboratories, biotechnology and biopharmaceutical researchers, veterinary providers, academic institutions and contract research organizations.

Its diagnostic portfolio spans infectious disease, autoimmune screening and livestock health. Human-health applications include multiplex antibody testing and inflammatory biomarker research. Veterinary work includes tests for Mycoplasma bovis and Johne’s disease, using specimens such as bovine serum and milk to support disease surveillance and eradication programmes. Some diagnostic panels remain in development, reflecting the company's continuing work with external research and commercial partners.

International development

Pictor established its global corporate headquarters in Carlsbad, California, in May 2025 as part of a U.S. corporate restructuring intended to accelerate commercialization. Its international operations encompass research and assay development in New Zealand, manufacturing and regional distribution in India, and commercial activities in Australia. The company also moved its primary web presence from its historical diagnostics domain to a proteomics-focused domain, reflecting the broader positioning of its targeted testing platform.